NCT00561834View on ClinicalTrials.gov

Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy

PHASE1CompletedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions

Nonarteritic Anterior Ischemic Optic Neuropathy

Interventions

DRUG

ranibizumab

All patients (n=15) will be treated with open label 0.5mg ranibizumab given intravitreally monthly as needed for 6 months.

Trial Locations (1)

80045-0510

Rocky Mountain Lions Eye Institute, Aurora

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

University of Colorado, Denver

OTHER